ReviewMolecular psychiatry2004
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
Review in Molecular psychiatry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 239 citations in OpenAlex.
- Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.Journal of child and adolescent psychopharmacology · 2009Trial
- Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study.Bipolar disorders · 2008Trial
- Biomarkers of cognitive and memory decline in psychotropic drug users.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Gallium-Based Liquid Metal Materials for Antimicrobial Applications.Bioengineering (Basel, Switzerland) · 2022Review
- The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.Frontiers in neuroscience · 2022Review
- CaBiomolecules · 2021Article
- Patient fibroblast circadian rhythms predict lithium sensitivity in bipolar disorder.Molecular psychiatry · 2021Article
- Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2.Molecular psychiatry · 2021Article
- Circadian rhythms in bipolar disorder patient-derived neurons predict lithium response: preliminary studies.Molecular psychiatry · 2021Article
- Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma.Biomedicines · 2021Review
- Lithium: a potential therapeutic strategy in obsessive-compulsive disorder by targeting the canonical WNT/β pathway.Translational psychiatry · 2021Review
- Review
- Valproate inhibits mitochondrial bioenergetics and increases glycolysis in Saccharomyces cerevisiae.Scientific reports · 2020Article
- Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation.Molecular neurobiology · 2019Review
- Dual Role of Autophagy in Diseases of the Central Nervous System.Frontiers in cellular neuroscience · 2019Review
- Differential Expression of Synapsin I and II upon Treatment by Lithium and Valproic Acid in Various Brain Regions.The international journal of neuropsychopharmacology · 2018Article
- PDE11A negatively regulates lithium responsivity.Molecular psychiatry · 2017Article
- Thyroid states regulate subcellular glucose phosphorylation activity in male mice.Endocrine connections · 2017Article
- Serotonin modulates a depression-like state in Drosophila responsive to lithium treatment.Nature communications · 2017Article
- Animal models to improve our understanding and treatment of suicidal behavior.Translational psychiatry · 2017Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Bipolar disorder afflicts approximately 1-3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.